188 related articles for article (PubMed ID: 21283157)
1. Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series.
Kohly RP; Muni RH; Kertes PJ; Lam WC
Can J Ophthalmol; 2011 Feb; 46(1):46-50. PubMed ID: 21283157
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab.
Almony A; Mansouri A; Shah GK; Blinder KJ
Can J Ophthalmol; 2011 Apr; 46(2):182-5. PubMed ID: 21708088
[TBL] [Abstract][Full Text] [Related]
3. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
Chen E; Kaiser RS; Vander JF
Retina; 2007; 27(4):445-50. PubMed ID: 17420696
[TBL] [Abstract][Full Text] [Related]
5. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy.
Cornish KS; Williams GJ; Gavin MP; Imrie FR
Eur J Ophthalmol; 2011; 21(4):440-5. PubMed ID: 21188681
[TBL] [Abstract][Full Text] [Related]
6. INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN ANGIOID STREAKS: Four-Year Follow-up.
Tilleul J; Mimoun G; Querques G; Puche N; Zerbib J; Lalloum F; Srour M; Souied EH
Retina; 2016 Mar; 36(3):483-91. PubMed ID: 26355947
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
[TBL] [Abstract][Full Text] [Related]
8. The use of intravitreal bevacizumab to treat choroidal neovascular membranes (CNVMs).
Derriman L; Marshall J; Moorman C; Downes SM
Retina; 2008 Jun; 28(6):910; author reply 910-1. PubMed ID: 18536613
[No Abstract] [Full Text] [Related]
9. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
Farah SE
Ophthalmic Surg Lasers Imaging; 2008; 39(4):294-8. PubMed ID: 18717434
[TBL] [Abstract][Full Text] [Related]
10. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
Veritti D; Sarao V; Lanzetta P
J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
13. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
14. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
16. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis.
Chiang A; Chang LK; Yu F; Sarraf D
Retina; 2008 Oct; 28(9):1265-9. PubMed ID: 18628724
[TBL] [Abstract][Full Text] [Related]
17. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
19. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
20. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NAIVE IDIOPATHIC CHOROIDAL NEOVASCULARIZATION: A Comparative Study.
Sudhalkar A; Yogi R; Chhablani J
Retina; 2015 Jul; 35(7):1368-74. PubMed ID: 25830696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]